Are hydroxyzine and metoprolol appropriate for treating a patient with anxiety and hypertension?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Hydroxyzine and Metoprolol for Anxiety with Hypertension

This combination is not recommended as first-line therapy for a patient with both anxiety and hypertension. According to current evidence-based guidelines, you should treat the hypertension with guideline-directed first-line agents (ACE inhibitors, ARBs, calcium channel blockers, or thiazides), and address the anxiety separately with appropriate anxiolytic therapy—but metoprolol is not a first-line antihypertensive, and hydroxyzine has limited long-term efficacy data for anxiety.

Why This Combination Falls Short

Metoprolol's Limited Role in Hypertension

Beta-blockers like metoprolol are NOT first-line agents for hypertension treatment. The 2024 ESC Guidelines explicitly state that ACE inhibitors, ARBs, dihydropyridine calcium channel blockers, and thiazide/thiazide-like diuretics are the recommended first-line treatments, with Class I, Level A evidence 1.

Beta-blockers should only be combined with these first-line agents when there are compelling indications such as:

  • Angina pectoris
  • Post-myocardial infarction
  • Heart failure with reduced ejection fraction
  • Need for heart rate control 1

Anxiety alone is not a compelling indication for beta-blocker use in hypertension. While older studies suggested metoprolol might help with anxiety-related blood pressure elevations 2, more recent evidence shows that:

  • Metoprolol at typical doses (<200 mg/day) does not eliminate the cardiovascular effects of anxiety 3
  • Beta-blockers are actually associated with increased risk of adverse psychiatric reactions, including anxiety disorders (aHR=1.51), depressive disorders (aHR=1.36), and sleep disorders (aHR=1.27) within the first two years of treatment 4

Hydroxyzine's Limitations for Anxiety

While hydroxyzine is FDA-approved for symptomatic relief of anxiety 5, there are significant concerns:

The FDA label explicitly states: "The effectiveness of hydroxyzine as an antianxiety agent for long term use, that is more than 4 months, has not been assessed by systematic clinical studies" 5. This is a critical limitation for managing chronic anxiety disorders.

Research evidence shows:

  • Hydroxyzine demonstrated efficacy over placebo in short-term studies (4 weeks to 3 months) for generalized anxiety disorder 6, 7
  • It showed comparable efficacy to bromazepam (a benzodiazepine) at 3 months 6
  • However, no robust long-term data exist beyond this timeframe

What the Anxiety Guidelines Actually Recommend

The 2023 Japanese guidelines for anxiety disorders prioritize:

  • First-line pharmacotherapy: SSRIs (escitalopram, sertraline, fluvoxamine, paroxetine) or SNRIs (venlafaxine) 8
  • Beta-blockers (atenolol, propranolol) are explicitly deprecated based on negative evidence 8
  • Hydroxyzine is not mentioned as a recommended agent in modern anxiety disorder guidelines

The Correct Approach

For Hypertension Management:

  1. Start with guideline-directed first-line therapy: ACE inhibitor or ARB combined with either a dihydropyridine calcium channel blocker or thiazide diuretic 1
  2. Use fixed-dose single-pill combinations when possible to improve adherence 1
  3. Target systolic BP of 120-129 mmHg if well tolerated 1

For Anxiety Management:

  1. First-line: SSRI (escitalopram or sertraline preferred) or SNRI (venlafaxine) 8
  2. Consider cognitive behavioral therapy as definitive treatment 8
  3. If short-term anxiolytic needed while waiting for SSRI/SNRI to take effect, benzodiazepines may provide more reliable BP reduction than hydroxyzine 9—though this should be time-limited

If Both Conditions Coexist:

  • Treat hypertension with standard first-line agents (these do not worsen anxiety)
  • Treat anxiety disorder with evidence-based pharmacotherapy (SSRIs/SNRIs)
  • Avoid beta-blockers given their association with increased psychiatric adverse reactions 4

Critical Caveats

Do not use metoprolol thinking it will "kill two birds with one stone." The evidence shows:

  • It's suboptimal for hypertension (not first-line)
  • It's ineffective for anxiety (may worsen psychiatric symptoms)
  • The combination with hydroxyzine provides no synergistic benefit

If the patient is already on metoprolol for a legitimate indication (post-MI, heart failure, etc.), then continuing it is appropriate—but don't add it solely for anxiety with hypertension.

Hydroxyzine may be reasonable for very short-term use (weeks, not months) while initiating definitive anxiety treatment, but recognize its limitations and plan for transition to evidence-based therapy 5, 6.

Related Questions

Can hydroxyzine be used for breakthrough anxiety in a patient taking Celexa (citalopram) 20 milligrams daily?
Is it appropriate to prescribe hydroxyzine 50 mg four times daily as needed (PRN) for anxiety, not exceeding a total daily dose of 200 mg?
In an 18-year-old female with hypertension on labetalol, no prior psychiatric history, a PHQ‑9 score of 8 and a GAD‑7 score of 13, who is experiencing racing thoughts and worsening anxiety after the death of a relative, should I start a low‑dose antidepressant for grief?
Should a 20-year-old male with anxiety on sertraline and alprazolam, who is self‑monitoring his blood pressure, be started on antihypertensive medication?
Can I increase the hydroxyzine dose for anxiety?
What are the cancer indications, standard drug doses, administration schedules, and key differences among the FOLFOX (folinic acid, fluorouracil, oxaliplatin) regimens—including FOLFOX-4, FOLFOX-6, FOLFOX-7, modified FOLFOX-6 (mFOLFOX-6), and other common variants?
Is tapering required when discontinuing baclofen after a short 3‑5‑day course of 10 mg three times daily for intractable hiccups?
What is the appropriate acute treatment for a hemorrhagic stroke in a patient with a history of prior ischemic infarcts?
What are the classifications of esophageal varices by size and endoscopic appearance, and how are gastric varices classified?
What are the normal and abnormal ranges for C-reactive protein and their clinical significance?
How should a crush injury of the index finger be managed?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.